Under most pessimistic scenario, one dose would avert fewer cervical cancer cases with difference of 3 percent over 100 years.

Feasibility study highlights an unmet need of patients receiving palliative radiotherapy for bone metastases pain, but the intervention was not as feasible for staff.

A mouse xenograft model of DLBCL tumors was used to characterize the role of TNFAIP3 expression tumor growth. Tumors induced from cells with higher levels of TNFAIP3 had a lower volume compared with ...

Researchers sought to determine factors related to complete response in managing LARC with total neoadjuvant therapy.

The median progression-free survival was 9.6 months in patients who received site-specific therapy and 6.6 months in patients who received empirical chemotherapy. Patients diagnosed with cancer of ...

Using sarcoma organoids, researchers were able to identify “active, approved, or recommended therapies” for 58% of patients screened. “We’ve shown that it’s possible to generate sarcoma organoids ...

Results of the AGAVE-201 trial demonstrate a high incidence of response to axatilimab among patients with chronic graft-versus-host disease.

The HYPOSIB trial supports moderately hypofractionated radiotherapy with simultaneous boost as a standard-of-care option that’s noninferior to sequential boost, said study discussant Kimberly Corbin, ...

In an adjusted analysis, omitting the 5-FU bolus decreased the risk of neutropenia and thrombocytopenia without impacting overall survival. Omitting the 5-fluorouracil (5-FU) bolus from 5-FU multidrug ...

Results of a secondary analysis of data from the ASPREE trial quantified the CVD burden for older adults after cancer and its treatment.

Adding pembrolizumab to pemetrexed and platinum-based chemotherapy did not improve outcomes in patients with EGFR-mutant, TKI-resistant, metastatic NSCLC.

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes than patients who received VRd alone.